**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 4597**

**Columns: CASE REPORT**

**Squamous cell carcinoma after radiofrequency ablation for Barrett’s dysplasia**

Zeki SS *et al*. SCC after RFA for Barrett’s oesophagus

Sebastian S Zeki*,* Rehan Haidry*,* Manuel Justo-Rodriguez*,* Laurence B Lovat*,* Nicholas A Wright*,* Stuart A McDonald

**Sebastian S Zeki, Nicholas A Wright,** **Stuart A McDonald,** Centre for Tumour Biology, Bart’s Cancer Institute, London EC1M 6BQ, United Kingdom

**Rehan Haidry, Laurence B Lovat,** Research Department of General Surgery, University College London, London WC1E 6BT, United Kingdom

**Manuel Justo-Rodriguez,** Department of Pathology, University College London, London WC1E 6BT, United Kingdom

**Author contributions**: Zeki SS designed and performed research; McDonald SA, Wright NA, Justo-Rodriguez M, Haidry R, Lovat LB contributed new reagents or analytic tools; Zeki SS analyzed data and wrote the paper.

**Correspondence to: Dr. Sebastian Zeki**, Centre for Tumor Biology, Bart’s Cancer Institute, Charterhouse Square, London, EC1M 6BQ, United Kingdom.

 sebastiz@hotmail.com

**Telephone:** +44-207-8827205 **Fax:** +44-207-8827205

**Received:** July 9, 2013  **Revised:** August 23, 2013

**Accepted:** September 4, 2013

 **Published online:**

**Abstract**

Barrett’s oesophagus (BO) is a usually indolent condition that occasionally requires endoscopic therapy. Radiofrequency ablation (RFA) is an effective endoscopic treatment for high grade dysplasia (HGD) and intramucosal cancer in BO. It has a good efficacy, durability and safety profile although complications can occur. Here we describe a case of RFA in a patient with high grade dysplasia. Although the response to treatment was initially very good with the development of neosquamous epithelium, the patient very rapidly developed a squamous cell cancer of the oesophagus confirmed on radiology, histology and immunohistochemistry. Sanger sequencing confirmed that the original HGD and the squamous cell cancer (SCC) were derived from separate clonal origins. The report highlights the fact that SCC of the oesophagus has been noted after endoscopic ablation for BO previously and suggest that ablation of BO may encourage the clonal expansion of cells carrying carcinogenic mutations once a dominant clonal population has been eradicated.

© 2013 Baishideng. All rights reserved.

**Key words:** Squamous carcinoma oesophagus; Barrett’s oesophagus; Radiofrequency ablation; Squamous cell cancer; High grade dysplasia

**Core tip:** The development of squamous cell cancer of the oesophagus after endoscopic ablation can happen and may add further weight to the argument for continued surveillance after radiofrequency ablation for Barrett’s related pathologies.

Zeki SS*,* Haidry R*,* Justo-Rodriguez M*,* LovatLB*,* Wright NA*,* McDonaldSA. Squamous cell carcinoma after radiofrequency ablation for Barrett’s dysplasia. *World J Gastroenterol* 2013;

**Available from:** URL: http://www.wjgnet.com/esps/

**DOI:** http://dx.doi.org/10.3748/wjg.v19.i0.0000

**INTRODUCTION**

Radiofrequency ablation (RFA) is an effective and safe treatment for the eradication of Barrett’s oesophagus (BO) related high grade dysplasia (HGD) and intramucosal cancer (IMC)[1]. Recent evidence suggests that Barrett’s related pathology can still recur after RFA[2,3]. There are also case reports on the occurrence of squamous carcinomas occurring after endoscopic ablation. Some evidence suggests that the a stem cell origin of Barrett’s mucosa may be common between squamous and columnar lined epithelium[4] although this relationship has not been demonstrated either with synchronous or metachronous Barrett’s and squamous carcinoma. Here we describe the first documented case of squamous carcinoma occurring after radiofrequency ablation and investigate its clonal relationship to the pre-treatment Barrett’ related HGD.

**CASE REPORT**

A 52-year old man was admitted to the endoscopy unit in November 2008 for routine surveillance of Barrett’s oesophagus which he had undergone since 2005. The Barrett’s segment extended between 26 and 38 cm. Quandrantic biopsies demonstrated columnar-lined non-dysplastic epithelium throughout the segment apart from biopsies taken at 38 cm which demonstrated a high grade dysplasia. This was confirmed on subsequent endoscopies in December 2008 and February 2009.

In April 2009 the patient underwent focussed radiofrequency ablation [RFA (HALO™ 90)] with a further session of circumferential RFA in June 2009. Further focal RFA was applied to several Barrett’s islands in December 2009 and June 2010. A follow up gastroscopy in September 2010 with quadrantic biopsies showed normal, non-dysplastic squamous re-epithelialisation in all biopsies between 28 to 38 cm apart from two isolated areas at 35 and 38 cm which showed intestinal metaplasia only on histology.

The patient underwent a further surveillance gastroscopy in August 2011. A large, ulcerating mass was found between 35 to 39 cm involving the GOJ. No intestinal metaplasia was seen.

Apart from two short tongues of Barrett’s that were separate to the ulcerating lesion the entire oesophagus was otherwise squamous-lined (Figure 1). The ulcerating lesion was characterized histologically as a squamous carcimoma (Figure 2) and confirmed immunophenotypically by p63 positivity (Figure 2B)**.** A staging computed tomography scan confirmed the squamous cell cancer to involve loco regional lymph nodes without distant metastases**.** The patient died prior to undergoing chemo-radiotherapy due to an unrelated pneumonia.

In order to further characterise the genotypic features of the Barrett’s related HGD and the squamous carcinoma, the samples underwent laser microdissection and sequencing of exons 5-9 of *TP53* and exon 2 of *CDKN2A* as previously described[5]. These are known to be commonly mutated in both squamous cell cancer and Barrett’s HGD[6].

The biopsy samples of HGD demonstrated a mutation of *CDKN2A* c.286 G>A (p.V100M)(Figure 1A) only.However the squamous cell cancer did not contain the mutation detected in HGD, but demonstrated a different mutation of*TP53*(Figure 2D).

**DISCUSSION**

A number of therapeutic modalities are now available for the treatment of Barrett’s oesophagus. Endoscopic therapies are now widely used and robust analyses have demonstrated efficacy in the treatment of HGD and intramucosal cancer[3,7]. Radiofrequency ablation of Barrett’s mucosa is a relatively safe technique with perforation and stricturing occurring less commonly than other endoscopic ablation techniques[1].

Our case is unique in that it shows the first demonstration of a squamous carcinoma occurring rapidly in an oesophageal segment recently treated with radiofrequency ablation for high-grade dysplasia.

There is a literature on the development of subsquamous Barrett’s after RFA with case reports demonstrating the rare development of adenocarcinoma in these areas[8]. There are also reports of squamous carcinoma occurring after ablation[9] although we have described the first case after RFA. The presence of squamous carcinoma in this and other reports so soon after a normal endoscopy subsequent to a successful ablation of Barrett’s related pathology indicates that patients may still warrant surveillance of neo-squamous epithelium after RFA. We have previously found somatic mutations in one case of normal squamous epithelium after radiofrequency ablation (accepted for publication by *Am J Gastro*). The fact that this may be a complication of RFA itself is indicated firstly by the absence of risk factors for squamous carcinoma development in this patient and secondly by the rapidity of its growth after RFA thermal injury. Thermal injury is already implicated as a causative factor in squamous carcinoma development [10,11] albeit over longer time courses.

Several studies have recently demonstrated a potential common progenitor for squamous and columnar epithelium by using mitochondrial and DNA mutations[4,5,12]. The fact that the two cancers are not clonally related on targeted sequencing of genes commonly mutated in both adenocarcinoma and squamous cell cancer indicates a different clonal origin of the two neoplasias. Given the squamous tumour was found at the same location as the previous Barrett’s HGD and morphologically was not a mixed adenosquamous type tumour, an alternative and interesting conjecture is that the eradication of Barrett’s dysplasia has allowed a protumorigenic clonal squamous population to proliferate. Such clonal competition has been suggested to occur in a number of different neoplasias including Barrett’s oesophagus[5]. An interesting and related issue also pertains to why metachronous squamous carcinoma and Barrett’s is so uncommon given the number of shared risk factors[13] and adds further weight to the idea that the clonal populations that characterise BO, or the phenotype of the tissue itself may protect against the development of squamous carcinoma.

**REFERENCES**

1 **Bulsiewicz WJ**, Kim HP, Dellon ES, Cotton CC, Pasricha S, Madanick RD, Spacek MB, Bream SE, Chen X, Orlando RC, Shaheen NJ. Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrett's esophagus. *Clin Gastroenterol Hepatol* 2013; **11**: 636-642 [PMID: 23103824 DOI: 10.1016/j.cgh.2012.10.028]

2 **Korst RJ**, Santana-Joseph S, Rutledge JR, Antler A, Bethala V, DeLillo A, Kutner D, Lee BE, Pazwash H, Pittman RH, Rahmin M, Rubinoff M. Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett's esophagus. *J Thorac Cardiovasc Surg* 2013; **145**: 1529-1534 [PMID: 23219501 DOI: 10.1016/j.jtcvs.2012.11.016]

3 **Shaheen NJ**, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, Sharma VK, Eisen GM, Fennerty MB, Hunter JG, Bronner MP, Goldblum JR, Bennett AE, Mashimo H, Rothstein RI, Gordon SR, Edmundowicz SA, Madanick RD, Peery AF, Muthusamy VR, Chang KJ, Kimmey MB, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Dumot JA, Falk GW, Galanko JA, Jobe BA, Hawes RH, Hoffman BJ, Sharma P, Chak A, Lightdale CJ. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. *Gastroenterology* 2011; **141**: 460-468 [PMID: 21679712 DOI: 10.1053/j.gastro.2011.04.061]

4 **Nicholson AM**, Graham TA, Simpson A, Humphries A, Burch N, Rodriguez-Justo M, Novelli M, Harrison R, Wright NA, McDonald SA, Jankowski JA. Barrett's metaplasia glands are clonal, contain multiple stem cells and share a common squamous progenitor. *Gut* 2012; **61**: 1380-1389 [PMID: 22200839 DOI: 10.1136/gutjnl-2011-301174]

5 **Leedham SJ**, Preston SL, McDonald SA, Elia G, Bhandari P, Poller D, Harrison R, Novelli MR, Jankowski JA, Wright NA. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. *Gut* 2008; **57**: 1041-1048 [PMID: 18305067 DOI: 10.1136/gut.2007.143339]

6 **Catalogue of Somatic Mutations in Cancer.** Available from: http: //cancer.sanger.ac.uk/cancergenome/projects/cosmic/

7 **Shaheen NJ**, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, Jobe BA, Eisen GM, Fennerty MB, Hunter JG, Fleischer DE, Sharma VK, Hawes RH, Hoffman BJ, Rothstein RI, Gordon SR, Mashimo H, Chang KJ, Muthusamy VR, Edmundowicz SA, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Falk GW, Kimmey MB, Madanick RD, Chak A, Lightdale CJ. Radiofrequency ablation in Barrett's esophagus with dysplasia. *N Engl J Med* 2009; **360**: 2277-2288 [PMID: 19474425 DOI: 10.1056/NEJMoa0808145]

8 **Titi M**, Overhiser A, Ulusarac O, Falk GW, Chak A, Wang K, Sharma P. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett's esophagus. *Gastroenterology* 2012; **143**: 564-6.e1 [PMID: 22561053 DOI: 10.1053/j.gastro.2012.04.051]

9 **Allende D**, Dumot J, Yerian L. Esophageal squamous cell carcinoma arising after endoscopic ablation therapy of Barrett's esophagus with high-grade dysplasia. Report of a case. *Dis Esophagus* 2013; **26**: 314-318 [PMID: 23009180 DOI: 10.1111/j.1442-2050.2012.01411.x]

10 **Ribeiro U**, Posner MC, Safatle-Ribeiro AV, Reynolds JC. Risk factors for squamous cell carcinoma of the oesophagus. *Br J Surg* 1996; **83**: 1174-1185 [PMID: 8983603]

11 **Islami F**, Boffetta P, Ren JS, Pedoeim L, Khatib D, Kamangar F. High-temperature beverages and foods and esophageal cancer risk--a systematic review. *Int J Cancer* 2009; **125**: 491-524 [PMID: 19415743 DOI: 10.1002/ijc.24445]

12 **Paulson TG**, Xu L, Sanchez C, Blount PL, Ayub K, Odze RD, Reid BJ. Neosquamous epithelium does not typically arise from Barrett's epithelium. *Clin Cancer Res* 2006; **12**: 1701-1706 [PMID: 16551852 DOI: 10.1158/1078-0432.CCR-05-1810]

13 **Streppel MM**, Siersema PD, de Leng WW, Morsink FH, Vleggaar FP, Maitra A, Montgomery EA, Offerhaus GJ. Squamous cell carcinoma in Barrett's esophagus: field effect versus metastasis. *Dis Esophagus* 2012; **25**: 630-637 [PMID: 22221671 DOI: 10.1111/j.1442-2050.2011.01300.x]

**P-Reviewers** Chai JY, Nagahara H, Tarnawski AS, Redondo-Cerezo E **S-Editor** Gou SX  **L-Editor E-Editor**

**Figure 1 Endoscopic, genetic and histological figures of the patient before and immediately after radiofrequency ablation for Barrett’s related high grade dysplasia.** A: Sanger sequencing from columnar lined oesophagus taken in June 2010 showing a mutation in *CDKN2A* c.286 G>A (p.V100M) (starred); B: Haematoxylin and eosin stain at × 10 magnification from a biopsy taken in June 2010. This demonstrates high grade dysplasia with nuclear pleiomorphism, increased nuclear: cytoplasmic ratio and disordered nuclei (arrow); C: Endoscopic view of the patient’s columnar-lined oesophagus (April 2009) showing classical salmon pink mucosa between 28cm and 36cm from the incisors; D: Endoscopic view of the patient’s re-epithelialized oesophagus (September 2010) after radiofrequency ablation.



**Figure 2 Endoscopic, genetic and histological figures of the patient after radiofrequency ablation**. A: Endoscopic view of a 4cm ulcerating mass between 35 to 39 cm; B: Example of positive p63 stain of the biopsies taken from the ulcerating mass (arrow); C: Haematoxylin and eosin stain of biopsies taken from the ulcer crater demonstrating invasive squamous cell cancer (arrow); D: Sanger sequencing of a mutation in *TP53* c.817 C>T p. R273C (upper panel, starred) Wild type Sanger sequence of *TP53* (lower panel).